Everyday Care in Action: Thousands of Kenvue Employees Come Together Across 21 Markets to Help Advance Healthier Communities
14.5.2025 12:45:00 CEST | Business Wire | Press Release
Kenvue Inc. (NYSE: KVUE), the maker of iconic brands such asNeutrogena®, Listerine®, Aveeno®, and Tylenol®, today announced its global community engagement efforts in celebration of Kenvue Cares Week, the company’s signature annual volunteer initiative part of its Healthy Lives Mission. Kenvue Cares Week is a testament to the strong Kenvue commitment to advance the well-being of people and our planet, giving back through volunteerism, and delivering meaningful, measurable impact in local communities.
Throughout the month of May, thousands of Kenvuers are coming together in 21 markets across six continents to support causes driven by the company’s commitments, creating 5,000+ hours of meaningful moments, building stronger connections with their communities, and demonstrating the power of everyday care in action. This marks a fourfold increase in site participation compared to the program’s inaugural year. This year, Kenvuers will help deliver approximately 22,000 hygiene kits, curated with over 110,000 products from across our iconic brands, including Neutrogena®, Listerine®, OGX®, Johnson’s® Baby and Aveeno®, to support the health and wellbeing of vulnerable communities, including those affected by natural disasters, homelessness and conflict.
“Kenvue Cares Week is a powerful example of our Purpose – realize the extraordinary power of everyday care - in action. Our more than 20,000 Kenvuers share a passion for bringing everyday care to life for our consumers and communities and we are proud of the impact we are helping deliver,” said Russell Dyer, Chief Corporate Affairs Officer, Kenvue.
“Save the Children has been working for over 100 years to ensure all children have a healthy start in life, the opportunity to learn, and protection from harm," said Luciana Bonifacio, Chief Development Officer of Save the Children U.S. "We can't achieve this ambitious mission alone, and the support of strategic partners like Kenvue is essential for building lasting change for kids in the U.S. and around the world. This Kenvue Cares Week, we're proud to come together for a shared purpose—to make a difference for the wellbeing of children and communities in the aftermath of crises."
“Kenvue Cares Week presents the ideal opportunity to strengthen our mission at GRACE to care for our community through direct service. The sharing of personal care products plays an essential role in our efforts to support the underserved and help our neighbors take care of themselves,” said Amanda Block, Founder and Director, GRACE, a Summit based nonprofit focused on meeting the needs of underserved neighbors with community resources.
Advancing Healthy Communities
Examples of the activities Kenvuers will participate in include:
North America
- Pack hygiene kits of Kenvue products for disaster relief with Heart to Heart International in the U.S. and with Save the Children in Canada.
- Plant trees in Guelph and Markham, Canada, to support reforestation.
- Distribute food with local partners GRACE and Bridges Outreach.
- Pack food donations with the Mattie N. Dixon Community Cupboard in Fort Washington, Pennsylvania.
Latin America:
- Build hygiene kits with Save the Children in Cali, Colombia and Mexico City, Mexico, and with Direct Relief in Sao Paulo and San Jose Dos Campos, Brazil.
- Build sanitary bathrooms and help promote hygiene habits with local partner Modulo Sanitario in Buenos Aires, Argentina.
- Renovate playgrounds at children’s villages with Aldeas Infantiles in Asunción, Paraguay.
Europe, Middle East, and Africa:
- Pack hygiene kits with Save the Children in Cape Town, South Africa; Spain, Madrid, and with In Kind Direct in high Wycombe, England.
- Participate in "plogging" (jogging and picking up litter at the same time) in Rotkreuz, Switzerland Host an Equity in STEM workshop in High Wycombe, England.
Asia-Pacific:
- Assemble hygiene kits with Save the Children in Sydney, Australia, Beijing, and Shanghai, China.
- Plant trees on Motuihe Island in Auckland, New Zealand.
- Support elderly care centers in Singapore through NTUC Health Day Care Centre.
- Pack food kits with the India Food Banking Network in Baddi and Mulund, India.
About Kenvue
Kenvue Inc. is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in consumers’ hands and earn a place in their hearts and homes. Learn more at www.kenvue.com.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements about management’s expectations of Kenvue’s future operating and financial performance, product development, market position and business strategy. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and other words of similar meaning. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kenvue and its affiliates. A list and descriptions of these risks, uncertainties and other factors can be found in Kenvue’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 29, 2024 and subsequent Quarterly Reports on Form 10-Q and other filings, available at www.kenvue.com or on request from Kenvue. Any forward-looking statement made in this release speaks only as of the date of this release. Kenvue undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or developments or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250514740041/en/
Contacts
Melissa Witt
media@kenvue.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom